Sovereign AI Fund

The portfolio includes frontier AI and bioengineering companies such as Callosum and Twig.

The UK’s Sovereign AI fund supports AI companies with capital and infrastructure to grow.

Analysis and perspectives on AI sovereignty, investment strategy, and scaling British AI companies from the UK's sovereign venture fund.

Sovereign AI developed its approach by consulting founders on scaling needs in the UK.

The R&D Procurement Scheme provides up to £100 million for British AI startups to develop and test technology with government support.

Sovereign AI participated in CuspAI’s $450 million Series B financing.

Sovereign AI is backing Isomorphic Labs, led by Sir Demis Hassabis, which is harnessing AI to reimagine drug discovery and compress decades of pharmaceutical research into years.

Sovereign AI has invested in OLIX, which is developing a new approach to AI inference infrastructure.

Sovereign AI is supporting IMU Biosciences with £1.57 million to create a population-scale immune dataset with UK Biobank.

Open roles across UK Sovereign AI's portfolio companies — live listings pulled directly from each company's own hiring system.

Suzanne Ashman has been appointed Managing Partner at Sovereign AI, selected from over 60 candidates through a competitive five-stage Civil Service process.

James Wise chairs Sovereign AI in a non-executive advisory capacity, with his interests managed under a conflicts statement agreed with the DSIT Permanent Secretary.

The UK’s Sovereign AI fund provides capital, compute resources, and strategic assets to AI founders.

The fund outlines its investment criteria, process, and public funding management.

Sovereign AI backs UK founders in compute, foundation models, health, scientific discovery, and AI safety.

The fund invests £1 million to £20 million in AI startups, offering capital, compute resources, visas, and strategic assets.